Precision BioSciences, Inc. (DTIL)
NASDAQ: DTIL · Real-Time Price · USD
7.26
+0.76 (11.69%)
At close: Nov 22, 2024, 4:00 PM
7.27
+0.01 (0.14%)
After-hours: Nov 22, 2024, 4:03 PM EST
Precision BioSciences Employees
Precision BioSciences had 109 employees as of December 31, 2023. The number of employees decreased by 89 or -44.95% compared to the previous year.
Employees
109
Change (1Y)
-89
Growth (1Y)
-44.95%
Revenue / Employee
$688,954
Profits / Employee
$79,110
Market Cap
55.69M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
111, Inc. | 1,520 |
Apyx Medical | 252 |
Cytosorbents | 186 |
Enzo Biochem | 136 |
Prelude Therapeutics | 128 |
Kronos Bio | 63 |
Milestone Scientific | 17 |
Immix Biopharma | 17 |
DTIL News
- 1 day ago - Precision BioSciences to Participate in Upcoming November Investor Conferences - Business Wire
- 7 days ago - Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B - Business Wire
- 18 days ago - Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 24 days ago - Precision BioSciences to Report Third Quarter Results on November 4, 2024 - Business Wire
- 25 days ago - Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 - Business Wire
- 4 weeks ago - Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress - Business Wire
- 4 weeks ago - Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B - Business Wire
- 4 weeks ago - Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences - Business Wire